Loading…
Virax Biolabs Group Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VRAX.
▼ -99.8% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $2.39 | $8.65 | $56.25 | $36.50 | |
| P/S | 174.5x | 111.7x | 237.3x | 37.0x | 265.1x |
| P/B | 0.3x | 0.2x | 0.3x | 1.1x | 0.2x |
| EPS | -$12.64 | -$40.62 | -$83.90 | -$128.25 | |
| Profit margin | -52093.71% | -40439.10% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RNAZTranscode Therapeutics, Inc. | $2.18 | — | 1.6x | — | -59.28% | $2.31M |
| CRISCuris Inc | $0.95 | 0.3x | 0.4x | — | — | $2.31M |
| OGENOragenics Inc | $0.52 | 0.5x | 0.4x | — | -1307.06% | $2.37M |
| AKANAkanda Corp | $3.89 |
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
Company description provided by Yahoo Finance.
| -95739.17% |
| -4304.81% |
| -63748.32% |
| ROE | -86.35% | -66.30% | -106.41% | -125.47% | -59.80% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $2.1M |
| ONCOOnconetix, Inc. | $0.61 | 0.0x | 0.2x | — | -105.23% | $2.42M |
| SHPHShuttle Pharmaceuticals Holdings, Inc. | $3.54 | 39.3x | 0.6x | — | -326.36% | $2.07M |